within Pharmacolibrary.Drugs.ATC.L;

model L01EX15
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.62,
    Cl             = 0.00027666666666666665,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.009000000000000001,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.107,
    k12             = 25.7,
    k21             = 25.7
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01EX15</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Pexidartinib is an orally administered small-molecule tyrosine kinase inhibitor primarily targeting the colony-stimulating factor-1 receptor (CSF1R). It is approved for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) that is associated with severe morbidity or functional limitations and is not amenable to improvement with surgery.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult patients with solid tumors and healthy subjects following oral administration; predominantly healthy adults or patients with TGCT.</p><h4>References</h4><ol><li><p>Zahir, H, et al., &amp; LaCreta, F (2023). Pharmacokinetics of the Multi-kinase Inhibitor Pexidartinib: Mass Balance and Dose Proportionality. <i>Clinical pharmacology in drug development</i> 12(2) 159–167. DOI:<a href=\"https://doi.org/10.1002/cpdd.1186\">10.1002/cpdd.1186</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36369799/\">https://pubmed.ncbi.nlm.nih.gov/36369799</a></p></li><li><p>Zahir, H, et al., &amp; LaCreta, F (2023). Dosing Recommendation Based on the Effects of Different Meal Types on Pexidartinib Pharmacokinetics in Healthy Subjects: Implementation of Model-informed Drug Development Strategy. <i>Clinical pharmacology in drug development</i> 12(5) 475–483. DOI:<a href=\"https://doi.org/10.1002/cpdd.1240\">10.1002/cpdd.1240</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36942508/\">https://pubmed.ncbi.nlm.nih.gov/36942508</a></p></li><li><p>Zahir, H, et al., &amp; LaCreta, F (2022). Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects. <i>Clinical pharmacokinetics</i> 61(11) 1623–1639. DOI:<a href=\"https://doi.org/10.1007/s40262-022-01172-9\">10.1007/s40262-022-01172-9</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36264536/\">https://pubmed.ncbi.nlm.nih.gov/36264536</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01EX15;
